GLP-1 injections promise dramatic weight loss, but five documented medical cases, expensive prescriptions and surprising weight-regain statistics reveal the potential downside for Seagoville and Crandall residents.
SEAGOVILLE/CRANDALL — Imagine losing 40 pounds, buying a smaller wardrobe, and celebrating your new appearance. It’s a miracle that is transformative.
However, only to discover that your stomach cannot tolerate dinner, your prescription costs hundreds of dollars monthly, and stopping the injections could bring much of the weight back.
For millions of Americans using GLP-1 medications, including Ozempic, Wegovy, Mounjaro and Zepbound, weight loss can be dramatic. Unfortunately, so can the potential complications.
From relentless vomiting and dehydration to serious gastrointestinal disorders, muscle loss and costly long-term treatment, these medications carry risks that deserve attention.
For families in Seagoville and Crandall already balancing groceries, housing, insurance and medical bills, the financial consequences can be as important as the physical ones.
Women Use GLP-1 Drugs More Than Men
A November 2025 KFF national survey found that 12% of American adults were taking GLP-1 medications for weight loss, diabetes or another condition.
Women were more likely to use the drugs than men:
| Population | Currently taking GLP-1 drugs |
|---|---|
| Women | 15% |
| Men | 9% |
| All adults | 12% |
The medications help regulate appetite, blood sugar and digestion. However, reducing hunger comes with an important tradeoff: food moves through the stomach more slowly.
For some patients, that slowdown becomes a serious problem.
The Side Effects Behind the Success Stories
Clinical trials of Wegovy found substantial gastrointestinal side effects.
| Side effect | Wegovy patients | Placebo patients |
|---|---|---|
| Nausea | 44% | 16% |
| Diarrhea | 30% | 16% |
| Vomiting | 25% | 6% |
| Constipation | 24% | 11% |
Most gastrointestinal symptoms are mild or moderate and often improve. However, 4.1% of Wegovy-treated adults experienced severe gastrointestinal reactions, compared with 0.9% receiving placebo.
Other concerns include gallbladder disease, pancreatitis, dehydration-related kidney injury and severe delayed stomach emptying, sometimes called gastroparesis.
Five Patients, Five Serious Medical Experiences
The following cases were documented through CNN reporting or published medical literature. They are not identified as Seagoville or Crandall residents.
Their experiences illustrate possible complications but do not establish how frequently they occur.
1. Joanie Knight — Louisiana
Knight developed severe gastroparesis after taking Ozempic. Doctors found that food was remaining in her stomach abnormally long, contributing to persistent nausea and vomiting.
Her condition became serious enough that she eventually underwent gastric bypass surgery to help manage the disorder.
2. Brenda Allen — Dallas, Texas
Allen received Wegovy for weight loss but reported continuing digestive problems long after discontinuing treatment.
She told CNN that severe vomiting caused dehydration and required urgent medical care. At the time of the 2023 report, she had not received a definitive diagnosis explaining her symptoms.
3. Emily Wright — Toronto, Canada
Wright lost approximately 80 pounds while taking Ozempic but developed severe gastroparesis and cyclic vomiting syndrome.
Her symptoms became so disruptive that she required hospitalization for dehydration and eventually took leave from her teaching job.
4. A 55-Year-Old Man — Published Medical Case
Doctors described a man with diabetes and stiff-person syndrome who developed confirmed severe gastric-emptying problems after beginning Ozempic.
He required prolonged hospitalization. His underlying neurological condition also complicated determining how much the medication contributed.
5. A 39-Year-Old Man — United Kingdom
A December 2025 medical case report described a man who rapidly increased his tirzepatide dosage without medical supervision.
He developed life-threatening low blood sugar, electrolyte disturbances, pneumonia and multiple-organ complications requiring intensive care.
Importantly, this was an overdose-related case, not an example of normal supervised dosing.
These experiences demonstrate the importance of distinguishing suspected drug reactions, established medical diagnoses and complications from inappropriate medication use.
Women vs. Men: Who Regains the Weight?
One of the most revealing findings comes from research examining patients after stopping tirzepatide, the medication in Zepbound.
A study published in JAMA Internal Medicine examined 308 participants who had already achieved substantial weight loss before discontinuing treatment.
After one year, the percentages who regained at least one-quarter of their previously lost weight were:
| Group | Regained at least 25% of lost weight |
|---|---|
| Women | 83.6% |
| Men | 79.8% |
| Combined | 82.5% |
The sex-specific figures are calculated from the study’s published participant counts. The differences were not statistically significant.
That distinction matters: these percentages do not mean patients regained 80% of their original body weight.
Separate research involving semaglutide found that participants regained approximately two-thirds of their previous weight loss, on average, during the year after stopping treatment.
In other words, reaching a goal weight does not necessarily mean the medication is no longer needed.
The Price Tag Can Be Painful
As of October 2026, manufacturer self-pay programs advertise the following prices for eligible patients without applicable insurance coverage.
| Medication | Advertised monthly price |
|---|---|
| Wegovy injection | $199 introductory; then $349 |
| Zepbound starting dose | $299 |
| Zepbound 5 mg | $399 |
| Zepbound higher doses | As low as $449 |
Prices depend on eligibility, dose and program terms.
At $349 for a 28-day supply, 12 Wegovy fills would cost $4,188. At $449, 12 Zepbound fills would total $5,388.
Those figures exclude appointments and other medical expenses.
For a household in Crandall or Seagoville, that money could otherwise cover substantial grocery, utility or transportation expenses.
And the costs may continue for years if ongoing treatment is needed to maintain results.
Losing Fat — And Potentially Muscle
Another concern is that not every pound lost represents fat.
Clinical research shows that GLP-1-associated weight reduction can include decreases in lean body mass, which includes muscle and other nonfat tissues.
A 2025 multidisciplinary medical advisory also warned about potential muscle and bone loss accompanying rapid weight reduction.
Maintaining adequate nutrition, consuming sufficient protein and participating in resistance exercise can help protect physical strength.
Rapid weight loss may also produce loose skin, changes in facial appearance and hair thinning.
What About Cancer and Other Risks?
Wegovy and Zepbound carry boxed warnings concerning thyroid C-cell tumors observed in rodents. Whether these drugs cause such tumors in humans remains unknown.
They should not be used by people with certain personal or family histories of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
The FDA has also warned about dosing mistakes involving unapproved compounded GLP-1 injections, some resulting in hospitalization.
Nevertheless, these medications have demonstrated substantial benefits for eligible patients.
Wegovy, for example, reduced major cardiovascular events in a large clinical trial involving adults with established cardiovascular disease and overweight or obesity.
What Seagoville and Crandall Residents Should Know
Before committing to injections, residents should discuss their medical history, prescription coverage, potential side effects and long-term weight-management plans with a qualified health care professional.
Persistent vomiting, severe abdominal pain, dehydration or an inability to tolerate food requires prompt medical evaluation.
Patients should not change their dosage or stop prescribed treatment without discussing an appropriate plan with their clinician.
For many people, GLP-1 medications provide meaningful medical benefits. For others, complications or costs may outweigh those advantages.
The biggest question is not simply how much weight a person can lose. It is whether the improvement can be maintained safely, affordably and over the long term.
